However, while chemical inhibition of Class I HDACs, including HDAC1, has shown promise in the treatment of blood cancers, no such inhibitors have been approved for clinical use against solid tumors52. The gene discussed is HDAC1; the disease is hematopoietic and lymphoid system neoplasm.